{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:27:00Z","timestamp":1759336020640,"version":"build-2065373602"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s00393-025-01676-2","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T07:41:42Z","timestamp":1752219702000},"page":"632-638","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Behandlung neuroimmunologischer Erkrankungen mit CAR-T-Zellen","Treatment of neuroimmunological diseases with chimeric antigen receptor (CAR) T\u00a0cells"],"prefix":"10.1007","volume":"84","author":[{"given":"Felix","family":"Fischbach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena Kristina","family":"Pfeffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Heesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel A.","family":"Friese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"issue":"16","key":"1676_CR1","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude\u00a0SL, Frey\u00a0N, Shaw\u00a0PA et\u00a0al (2014) Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. N\u00a0Engl J Med 371(16):1507\u20131517. https:\/\/doi.org\/10.1056\/NEJMoa1407222","journal-title":"N Engl J Med"},{"issue":"8","key":"1676_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller\u00a0F, Taubmann\u00a0J, Bucci\u00a0L et\u00a0al (2024) CD19 CAR T\u2011Cell Therapy in Autoimmune Disease\u2014A Case Series with Follow-up. N\u00a0Engl J Med 390(8):687\u2013700. https:\/\/doi.org\/10.1056\/NEJMoa2308917","journal-title":"N Engl J Med"},{"issue":"12","key":"1676_CR3","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","volume":"22","author":"A Haghikia","year":"2023","unstructured":"Haghikia\u00a0A, Hegelmaier\u00a0T, Wolleschak\u00a0D et\u00a0al (2023) Anti-CD19 CAR T\u00a0cells for refractory myasthenia gravis. Lancet Neurol 22(12):1104\u20131105. https:\/\/doi.org\/10.1016\/S1474-4422(23)00375-7","journal-title":"Lancet Neurol"},{"key":"1676_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.03.002","author":"F Fischbach","year":"2024","unstructured":"Fischbach\u00a0F, Richter\u00a0J, Pfeffer\u00a0LK et\u00a0al (2024) CD19-targeted chimeric antigen receptor T\u00a0cell therapy in two patients with multiple sclerosis. Med. https:\/\/doi.org\/10.1016\/j.medj.2024.03.002","journal-title":"Med."},{"issue":"7","key":"1676_CR5","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser\u00a0SL, Waubant\u00a0E, Arnold\u00a0DL et\u00a0al (2008) B\u2011Cell Depletion with Rituximab in Relapsing\u2013Remitting Multiple Sclerosis. N\u00a0Engl J Med 358(7):676\u2013688. https:\/\/doi.org\/10.1056\/NEJMoa0706383","journal-title":"N Engl J Med"},{"issue":"12","key":"1676_CR6","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/s41577-022-00718-z","volume":"22","author":"KE Attfield","year":"2022","unstructured":"Attfield\u00a0KE, Jensen\u00a0LT, Kaufmann\u00a0M, Friese\u00a0MA, Fugger\u00a0L (2022) The immunology of multiple sclerosis. Nat Rev Immunol 22(12):734\u2013750. https:\/\/doi.org\/10.1038\/s41577-022-00718-z","journal-title":"Nat Rev Immunol"},{"issue":"26","key":"1676_CR7","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus\u00a0NE (2016) Myasthenia Gravis. N\u00a0Engl J Med 375(26):2570\u20132581. https:\/\/doi.org\/10.1056\/NEJMra1602678","journal-title":"N Engl J Med"},{"issue":"2","key":"1676_CR8","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41582-023-00916-w","volume":"20","author":"R Iorio","year":"2024","unstructured":"Iorio\u00a0R (2024) Myasthenia gravis: the changing treatment landscape in the era of molecular therapies. Nat Rev Neurol 20(2):84\u201398. https:\/\/doi.org\/10.1038\/s41582-023-00916-w","journal-title":"Nat Rev Neurol"},{"key":"1676_CR9","volume-title":"Diagnostik und Therapie myasthener Syndrome, S2k-Leitlinie. Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg), Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie","author":"H Wiendl","year":"2024","unstructured":"Wiendl\u00a0H, Meisel\u00a0A, Marx\u00a0A et\u00a0al (2024) Diagnostik und Therapie myasthener Syndrome, S2k-Leitlinie. Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg), Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie (www.dgn.org\/leitlinien (abgerufen am 16042025))"},{"issue":"9451","key":"1676_CR10","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","volume":"364","author":"VA Lennon","year":"2004","unstructured":"Lennon\u00a0VA, Wingerchuk\u00a0DM, Kryzer\u00a0TJ et\u00a0al (2004) A\u00a0serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364(9451):2106\u20132112. https:\/\/doi.org\/10.1016\/S0140-6736(04)17551-X","journal-title":"Lancet"},{"issue":"9","key":"1676_CR11","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.biocel.2012.06.013","volume":"44","author":"J Ratelade","year":"2012","unstructured":"Ratelade\u00a0J, Verkman\u00a0AS (2012) Neuromyelitis optica: Aquaporin\u20114 based pathogenesis mechanisms and new therapies. Int J Biochem Cell Biol 44(9):1519\u20131530. https:\/\/doi.org\/10.1016\/j.biocel.2012.06.013","journal-title":"Int J Biochem Cell Biol"},{"key":"1676_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1137998","author":"O Corbali","year":"2023","unstructured":"Corbali\u00a0O, Chitnis\u00a0T (2023) Pathophysiology of myelin oligodendrocyte glycoprotein antibody disease. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2023.1137998","journal-title":"Front Neurol"},{"issue":"9","key":"1676_CR13","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1056\/NEJMra1708712","volume":"378","author":"J Dalmau","year":"2018","unstructured":"Dalmau\u00a0J, Graus\u00a0F (2018) Antibody-Mediated Encephalitis. N\u00a0Engl J Med 378(9):840\u2013851. https:\/\/doi.org\/10.1056\/NEJMra1708712","journal-title":"N Engl J Med"},{"issue":"10","key":"1676_CR14","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41582-024-01012-3","volume":"20","author":"MC Dalakas","year":"2024","unstructured":"Dalakas\u00a0MC (2024) Stiff-person syndrome and related disorders\u2014diagnosis, mechanisms and therapies. Nat Rev Neurol 20(10):587\u2013601. https:\/\/doi.org\/10.1038\/s41582-024-01012-3","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"1676_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S1474-4422(10)70253-2","volume":"10","author":"J Dalmau","year":"2011","unstructured":"Dalmau\u00a0J, Lancaster\u00a0E, Martinez-Hernandez\u00a0E, Rosenfeld\u00a0MR, Balice-Gordon\u00a0R (2011) Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. lancet Neurol 10(1):63\u201374. https:\/\/doi.org\/10.1016\/S1474-4422(10)70253-2","journal-title":"lancet Neurol"},{"issue":"7","key":"1676_CR16","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","volume":"22","author":"V Granit","year":"2023","unstructured":"Granit\u00a0V, Benatar\u00a0M, Kurtoglu\u00a0M et\u00a0al (2023) Safety and clinical activity of autologous RNA chimeric antigen receptor T\u2011cell therapy in myasthenia gravis (MG-001): a\u00a0prospective, multicentre, open-label, non-randomised phase\u00a01b\/2a study. Lancet Neurol 22(7):578\u2013590. https:\/\/doi.org\/10.1016\/S1474-4422(23)00194-1","journal-title":"Lancet Neurol"},{"key":"1676_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s44321-024-00043-z","author":"DS Tian","year":"2024","unstructured":"Tian\u00a0DS, Qin\u00a0C, Dong\u00a0MH et\u00a0al (2024) B\u00a0cell lineage reconstitution underlies CAR-T\u00a0cell therapeutic efficacy in patients with refractory myasthenia gravis. EMBO Mol Med. https:\/\/doi.org\/10.1038\/s44321-024-00043-z","journal-title":"EMBO Mol Med"},{"issue":"11","key":"1676_CR18","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.neuron.2024.04.014","volume":"112","author":"J Motte","year":"2024","unstructured":"Motte\u00a0J, Sgodzai\u00a0M, Schneider-Gold\u00a0C et\u00a0al (2024) Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T\u00a0cells. Neuron 112(11):1757\u20131763.e2. https:\/\/doi.org\/10.1016\/j.neuron.2024.04.014","journal-title":"Neuron"},{"issue":"11","key":"1676_CR19","doi-asserted-by":"publisher","first-page":"101794","DOI":"10.1016\/j.xcrm.2024.101794","volume":"5","author":"J Wickel","year":"2024","unstructured":"Wickel\u00a0J, Schnetzke\u00a0U, Sayer-Klink\u00a0A et\u00a0al (2024) Anti-CD19 CAR-T\u00a0cells are effective in severe idiopathic Lambert-Eaton myasthenic syndrome. Cell Rep Med 5(11):101794. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101794","journal-title":"Cell Rep Med"},{"issue":"1","key":"1676_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","volume":"8","author":"C Qin","year":"2023","unstructured":"Qin\u00a0C, Tian\u00a0DS, Zhou\u00a0LQ et\u00a0al (2023) Anti-BCMA CAR T\u2011cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase\u00a01\u00a0trial interim results. Signal Transduct Target Ther 8(1):5. https:\/\/doi.org\/10.1038\/s41392-022-01278-3","journal-title":"Signal Transduct Target Ther"},{"key":"1676_CR21","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200292","author":"JM Cabrera-Maqueda","year":"2024","unstructured":"Cabrera-Maqueda\u00a0JM, Sepulveda\u00a0M, Garc\u00eda\u00a0RR et\u00a0al (2024) CD19-Directed CAR T\u2011Cells in a\u00a0Patient With Refractory MOGAD. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000200292","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1676_CR22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2403227121","author":"S Faissner","year":"2024","unstructured":"Faissner\u00a0S, Motte\u00a0J, Sgodzai\u00a0M et\u00a0al (2024) Successful use of anti-CD19 CAR T\u00a0cells in severe treatment-refractory stiff-person syndrome. Proc Natl Acad Sci USA. https:\/\/doi.org\/10.1073\/pnas.2403227121","journal-title":"Proc Natl Acad Sci USA"},{"key":"1676_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.03.018","author":"AC Pecher","year":"2025","unstructured":"Pecher\u00a0AC, Hensen\u00a0L, Schairer-Marquardt\u00a0R et\u00a0al (2025) Relapse after anti-CD19 CAR T\u2011cell therapy in a\u00a0patient with severe rheumatoid arthritis and multiple sclerosis effectively treated by autologous stem cell transplantation. Ann Rheum Dis. https:\/\/doi.org\/10.1016\/j.ard.2025.03.018","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1676_CR24","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1172\/JCI46110","volume":"121","author":"B Savoldo","year":"2011","unstructured":"Savoldo\u00a0B, Ramos\u00a0CA, Liu\u00a0E et\u00a0al (2011) CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T\u00a0cells in lymphoma patients. J\u00a0Clin Investig 121(5):1822\u20131826. https:\/\/doi.org\/10.1172\/JCI46110","journal-title":"J Clin Investig"},{"key":"1676_CR25","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008226","author":"ML Davila","year":"2014","unstructured":"Davila\u00a0ML, Riviere\u00a0I, Wang\u00a0X et\u00a0al (2014) Efficacy and Toxicity Management of 19\u201328z CAR T\u00a0Cell Therapy in B\u00a0Cell Acute Lymphoblastic Leukemia. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.3008226","journal-title":"Sci Transl Med"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01676-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-025-01676-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01676-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T10:06:30Z","timestamp":1759313190000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-025-01676-2"}},"subtitle":["Erfahrung und neue Entwicklungen","Experience and new developments"],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1676"],"URL":"https:\/\/doi.org\/10.1007\/s00393-025-01676-2","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"type":"print","value":"0340-1855"},{"type":"electronic","value":"1435-1250"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"1 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F.\u00a0Fischbach, L.K.\u00a0Pfeffer, C.\u00a0Heesen und M.A.\u00a0Friese geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}